Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70771-1902-06 70771-1902 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
67184-0531-03 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb 13, 2023 In Use
43598-0045-63 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov 30, 2022 In Use
42388-0024-37 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb 27, 2019 In Use
63020-0040-90 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sep 15, 2021 Mar 31, 2025 No Longer Used
00378-1201-78 00378-1201 Sorafenib Sorafenib Tosylate 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral Jun 1, 2022 In Use
60505-4779-05 60505-4779 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct 19, 2023 In Use
60505-3802-00 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
00002-5562-60 00002-5562 Selpercatinib RETEVMO 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral Apr 10, 2024 In Use
70437-0240-26 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
72819-0185-09 72819-0185 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 1, 2022 In Use
24338-0155-01 24338-0155 Nilotinib DANZITEN 95.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 30, 2024 In Use
60505-3816-03 60505-3816 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
59651-0544-15 59651-0544 DASATINIB DASATINIB 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
70710-1745-03 70710-1745 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
60505-3802-07 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
68001-0622-05 68001-0622 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 5, 2025 In Use
60687-0882-21 60687-0882 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 19, 2025 In Use
72205-0081-30 72205-0081 Erlotinib Hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
83076-1025-03 83076-1025 Ensartinib ENSACOVE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Oral Apr 30, 2025 In Use
59651-0543-15 59651-0543 DASATINIB DASATINIB 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
81927-0201-01 81927-0201 Imatinib oral IMKELDI 80.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 19, 2024 In Use
00310-1350-30 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 13, 2015 In Use
60505-3802-02 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
68180-0391-06 68180-0391 IMATINIB IMATINIB MESYLATE 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jul 8, 2019 In Use

Found 11564 results — Export these results